Please wait while the formulary information is being retrieved.
Drug overview for CLINDAMYCIN PHOSPHATE-D5W (clindamycin phosphate/dextrose 5 % in water):
Generic name: CLINDAMYCIN PHOSPHATE/DEXTROSE 5 % IN WATER (KLIN-da-MYE-sin)
Drug class: Clindamycin Systemic
Therapeutic class: Anti-Infective Agents
Clindamycin, a lincosamide antibiotic, is a derivative of lincomycin.
Clindamycin is used for the treatment of certain serious infections caused by susceptible aerobic gram-positive bacteria (staphylococci, streptococci, pneumococci) and for the treatment of certain serious infections caused by susceptible anaerobic bacteria. Use of clindamycin generally should be reserved for the treatment of serious infections when less toxic anti-infectives cannot be used (e.g., penicillin-allergic patients or other patients for whom a penicillin is inappropriate). Because clindamycin has been associated with potentially fatal colitis (see Cautions: GI Effects), the manufacturer recommends that clinicians consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).
Certain infections may require incision and drainage or other indicated surgical procedures in addition to anti-infective treatment. Use of clindamycin does not eliminate the need for surgical procedures when indicated. Because clindamycin does not distribute adequately into the CNS, the drug should not be used for the treatment of meningitis.
Generic name: CLINDAMYCIN PHOSPHATE/DEXTROSE 5 % IN WATER (KLIN-da-MYE-sin)
Drug class: Clindamycin Systemic
Therapeutic class: Anti-Infective Agents
Clindamycin, a lincosamide antibiotic, is a derivative of lincomycin.
Clindamycin is used for the treatment of certain serious infections caused by susceptible aerobic gram-positive bacteria (staphylococci, streptococci, pneumococci) and for the treatment of certain serious infections caused by susceptible anaerobic bacteria. Use of clindamycin generally should be reserved for the treatment of serious infections when less toxic anti-infectives cannot be used (e.g., penicillin-allergic patients or other patients for whom a penicillin is inappropriate). Because clindamycin has been associated with potentially fatal colitis (see Cautions: GI Effects), the manufacturer recommends that clinicians consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).
Certain infections may require incision and drainage or other indicated surgical procedures in addition to anti-infective treatment. Use of clindamycin does not eliminate the need for surgical procedures when indicated. Because clindamycin does not distribute adequately into the CNS, the drug should not be used for the treatment of meningitis.
DRUG IMAGES
No Image Available
The following indications for CLINDAMYCIN PHOSPHATE-D5W (clindamycin phosphate/dextrose 5 % in water) have been approved by the FDA:
Indications:
Anaerobic endometritis
Anaerobic joint infection
Anaerobic lung abscess
Anaerobic pelvic cellulitis
Anaerobic peritonitis
Anaerobic pneumonia
Anaerobic tubo-ovarian abscess
Clostridium perfringens empyema
Gas gangrene caused by Clostridium perfringens
Intra-abdominal anaerobic abscess
Pneumococcal pneumonia
Postsurgical vaginal cuff anaerobic infections
Sepsis caused by anaerobic bacteria
Skin and skin structure anaerobic infection
Skin and skin structure Streptococcus pyogenes infection
Staphylococcal pneumonia
Staphylococcal septicemia
Staphylococcus aureus osteomyelitis
Staphylococcus aureus skin and skin structure infection
Streptococcal pneumonia
Streptococcal septicemia
Professional Synonyms:
Abdominal abscess due to anaerobic bacteria
Anaerobic sepsis
Clostridium perfringens gas gangrene
Empyema due to Clostridium perfringens
Endometritis due to anaerobic bacteria
Gas gangrene due to Clostridium perfringens
Infection of the lungs due to anaerobic bacteria
Joint infection due to anaerobic bacteria
Lung abscess due to anaerobic bacteria
Osteomyelitis due to Staphylococcus aureus
Osteomyelitis due to Staphylococcus pyogenes aureus
Parametritis due to anaerobic bacteria
Pelvic cellulitis due to anaerobic bacteria
Peritonitis due to anaerobic bacteria
Pneumonia due to Staphylococcus species
Pneumonia due to Staphylococcus spp.
Pneumonia due to Streptococcus pneumoniae
Pneumonia due to Streptococcus species
Pneumonia due to Streptococcus spp.
Postsurgical anaerobic vaginal cuff infection
Pyogenic bone infection due to Staphylococcus aureus
Pyothorax due to Clostridium perfringens
Septicemia due to Staphylococcus species
Septicemia due to Staphylococcus spp.
Skin & skin soft tissue Streptococcus pyogenes infection
Skin and skin soft tissue Staphylococcus aureus infection
Staphylococcal sepsis
Streptococcal sepsis
Tubo-ovarian abscess due to anaerobic bacteria
Indications:
Anaerobic endometritis
Anaerobic joint infection
Anaerobic lung abscess
Anaerobic pelvic cellulitis
Anaerobic peritonitis
Anaerobic pneumonia
Anaerobic tubo-ovarian abscess
Clostridium perfringens empyema
Gas gangrene caused by Clostridium perfringens
Intra-abdominal anaerobic abscess
Pneumococcal pneumonia
Postsurgical vaginal cuff anaerobic infections
Sepsis caused by anaerobic bacteria
Skin and skin structure anaerobic infection
Skin and skin structure Streptococcus pyogenes infection
Staphylococcal pneumonia
Staphylococcal septicemia
Staphylococcus aureus osteomyelitis
Staphylococcus aureus skin and skin structure infection
Streptococcal pneumonia
Streptococcal septicemia
Professional Synonyms:
Abdominal abscess due to anaerobic bacteria
Anaerobic sepsis
Clostridium perfringens gas gangrene
Empyema due to Clostridium perfringens
Endometritis due to anaerobic bacteria
Gas gangrene due to Clostridium perfringens
Infection of the lungs due to anaerobic bacteria
Joint infection due to anaerobic bacteria
Lung abscess due to anaerobic bacteria
Osteomyelitis due to Staphylococcus aureus
Osteomyelitis due to Staphylococcus pyogenes aureus
Parametritis due to anaerobic bacteria
Pelvic cellulitis due to anaerobic bacteria
Peritonitis due to anaerobic bacteria
Pneumonia due to Staphylococcus species
Pneumonia due to Staphylococcus spp.
Pneumonia due to Streptococcus pneumoniae
Pneumonia due to Streptococcus species
Pneumonia due to Streptococcus spp.
Postsurgical anaerobic vaginal cuff infection
Pyogenic bone infection due to Staphylococcus aureus
Pyothorax due to Clostridium perfringens
Septicemia due to Staphylococcus species
Septicemia due to Staphylococcus spp.
Skin & skin soft tissue Streptococcus pyogenes infection
Skin and skin soft tissue Staphylococcus aureus infection
Staphylococcal sepsis
Streptococcal sepsis
Tubo-ovarian abscess due to anaerobic bacteria
The following dosing information is available for CLINDAMYCIN PHOSPHATE-D5W (clindamycin phosphate/dextrose 5 % in water):
Dosage of clindamycin hydrochloride, clindamycin palmitate hydrochloride, and clindamycin phosphate is expressed in terms of clindamycin.
Dosage and duration of treatment depend on the severity of the infection. If clindamycin is used in infections caused by Streptococcus pyogenes (group A beta-hemolytic streptococci; GAS), therapy should be continued for at least 10 days. At least 6 weeks of therapy may be required for certain serious infections (e.g., osteomyelitis).
When clindamycin oral solution is used in pediatric patients, the manufacturer recommends 8-12 mg/kg daily for the treatment of serious infections, 13-16 mg/kg daily for severe infections, and 17-25 mg/kg daily for more severe infections; daily dosage is given in 3 or 4 equally divided doses. In pediatric patients weighing 10 kg or less, the manufacturer recommends a minimum clindamycin dosage of 37.5 mg 3 times daily.
When oral clindamycin is used in neonates 7 days of age or younger, the American Academy of Pediatrics (AAP) recommends a dosage of 5 mg/kg every 12 hours in those weighing 2 kg or less or 5 mg/kg every 8 hours in those weighing more than 2 kg.
In neonates 8-28 days of age, AAP recommends an oral clindamycin dosage of 5 mg/kg every 8 hours in those weighing 2 kg or less or 5 mg/kg every 6 hours in those weighing more than 2 kg. In extremely low-birthweight neonates (less than 1 kg), a dosage of 5 mg/kg every 12 hours can be considered until 2 weeks of age.
When clindamycin capsules are used in pediatric patients able to swallow capsules, the manufacturer recommends 8-16 mg/kg daily given in 3 or 4 equally divided doses for the treatment of serious infections or 16-20 mg/kg daily given in 3 or 4 equally divided doses for more severe infections.
When the oral solution is used in pediatric patients, the manufacturer recommends 8-12 mg/kg daily for the treatment of serious infections, 13-16 mg/kg daily for severe infections, and 17-25 mg/kg daily for more severe infections; daily dosage is given in 3 or 4 equally divided doses. In pediatric patients weighing 10 kg or less, the manufacturer recommends a minimum dosage of 37.5 mg 3 times daily.
When oral clindamycin is used in pediatric patients beyond the neonatal period, AAP recommends a dosage of 10-25 mg/kg daily given in 3 equally divided doses for the treatment of mild to moderate infections or 30-40 mg/kg daily given in 3 or 4 equally divided doses for the treatment of severe infections.
The usual adult dosage of oral clindamycin is 150-300 mg every 6 hours for the treatment of serious infections or 300-450 mg every 6 hours for the treatment of more severe infections.
The manufacturer recommends that neonates younger than 1 month of age receive IM or IV clindamycin in a dosage of 15-20 mg/kg daily given in 3 or 4 equally divided doses. The lower dosage may be adequate for small, premature neonates.
When IM or IV clindamycin is used in neonates 7 days of age or younger, AAP recommends 5 mg/kg every 12 hours in those weighing 2 kg or less or 5 mg/kg every 8 hours in those weighing more than 2 kg.
In neonates 8-28 days of age, AAP recommends an IM or IV clindamycin dosage of 5 mg/kg every 8 hours in those weighing 2 kg or less or 5 mg/kg every 6 hours in those weighing more than 2 kg. In extremely low-birthweight neonates (less than 1 kg), a dosage of 5 mg/kg every 12 hours can be considered until 2 weeks of age.
The IM or IV dosage of clindamycin recommended by the manufacturer for infants and children 1 month of age or older is 20-40 mg/kg daily administered in 3 or 4 equally divided doses; the higher dosage should be used for more severe infections. Alternatively, the manufacturer states that these infants and children may receive 350 mg/m2 daily for the treatment of serious infections or 450 mg/m2 daily for the treatment of more severe infections.
In pediatric patients beyond the neonatal period, AAP recommends an IM or IV clindamycin dosage of 20-30 mg/kg daily given in 3 equally divided doses for the treatment of mild to moderate infections or 40 mg/kg daily given in 3 or 4 equally divided doses for the treatment of severe infections.
The recommended adult dosage of IM or IV clindamycin is 600 mg to 1.2 g daily given in 2-4 equally divided doses for the treatment of serious infections or 1.2-2.7
g daily given in 2-4 equally divided doses for the treatment of more severe infections. In the treatment of life-threatening infections, adult IV dosage may be increased to a maximum of 4.8 g daily.
If continuous IV infusion of clindamycin is used to maintain serum clindamycin concentrations above 4-6 mcg/mL in adults, an initial dose is given by rapid IV infusion prior to continuous IV infusion. (See Table 1.)
Dosage and duration of treatment depend on the severity of the infection. If clindamycin is used in infections caused by Streptococcus pyogenes (group A beta-hemolytic streptococci; GAS), therapy should be continued for at least 10 days. At least 6 weeks of therapy may be required for certain serious infections (e.g., osteomyelitis).
When clindamycin oral solution is used in pediatric patients, the manufacturer recommends 8-12 mg/kg daily for the treatment of serious infections, 13-16 mg/kg daily for severe infections, and 17-25 mg/kg daily for more severe infections; daily dosage is given in 3 or 4 equally divided doses. In pediatric patients weighing 10 kg or less, the manufacturer recommends a minimum clindamycin dosage of 37.5 mg 3 times daily.
When oral clindamycin is used in neonates 7 days of age or younger, the American Academy of Pediatrics (AAP) recommends a dosage of 5 mg/kg every 12 hours in those weighing 2 kg or less or 5 mg/kg every 8 hours in those weighing more than 2 kg.
In neonates 8-28 days of age, AAP recommends an oral clindamycin dosage of 5 mg/kg every 8 hours in those weighing 2 kg or less or 5 mg/kg every 6 hours in those weighing more than 2 kg. In extremely low-birthweight neonates (less than 1 kg), a dosage of 5 mg/kg every 12 hours can be considered until 2 weeks of age.
When clindamycin capsules are used in pediatric patients able to swallow capsules, the manufacturer recommends 8-16 mg/kg daily given in 3 or 4 equally divided doses for the treatment of serious infections or 16-20 mg/kg daily given in 3 or 4 equally divided doses for more severe infections.
When the oral solution is used in pediatric patients, the manufacturer recommends 8-12 mg/kg daily for the treatment of serious infections, 13-16 mg/kg daily for severe infections, and 17-25 mg/kg daily for more severe infections; daily dosage is given in 3 or 4 equally divided doses. In pediatric patients weighing 10 kg or less, the manufacturer recommends a minimum dosage of 37.5 mg 3 times daily.
When oral clindamycin is used in pediatric patients beyond the neonatal period, AAP recommends a dosage of 10-25 mg/kg daily given in 3 equally divided doses for the treatment of mild to moderate infections or 30-40 mg/kg daily given in 3 or 4 equally divided doses for the treatment of severe infections.
The usual adult dosage of oral clindamycin is 150-300 mg every 6 hours for the treatment of serious infections or 300-450 mg every 6 hours for the treatment of more severe infections.
The manufacturer recommends that neonates younger than 1 month of age receive IM or IV clindamycin in a dosage of 15-20 mg/kg daily given in 3 or 4 equally divided doses. The lower dosage may be adequate for small, premature neonates.
When IM or IV clindamycin is used in neonates 7 days of age or younger, AAP recommends 5 mg/kg every 12 hours in those weighing 2 kg or less or 5 mg/kg every 8 hours in those weighing more than 2 kg.
In neonates 8-28 days of age, AAP recommends an IM or IV clindamycin dosage of 5 mg/kg every 8 hours in those weighing 2 kg or less or 5 mg/kg every 6 hours in those weighing more than 2 kg. In extremely low-birthweight neonates (less than 1 kg), a dosage of 5 mg/kg every 12 hours can be considered until 2 weeks of age.
The IM or IV dosage of clindamycin recommended by the manufacturer for infants and children 1 month of age or older is 20-40 mg/kg daily administered in 3 or 4 equally divided doses; the higher dosage should be used for more severe infections. Alternatively, the manufacturer states that these infants and children may receive 350 mg/m2 daily for the treatment of serious infections or 450 mg/m2 daily for the treatment of more severe infections.
In pediatric patients beyond the neonatal period, AAP recommends an IM or IV clindamycin dosage of 20-30 mg/kg daily given in 3 equally divided doses for the treatment of mild to moderate infections or 40 mg/kg daily given in 3 or 4 equally divided doses for the treatment of severe infections.
The recommended adult dosage of IM or IV clindamycin is 600 mg to 1.2 g daily given in 2-4 equally divided doses for the treatment of serious infections or 1.2-2.7
g daily given in 2-4 equally divided doses for the treatment of more severe infections. In the treatment of life-threatening infections, adult IV dosage may be increased to a maximum of 4.8 g daily.
If continuous IV infusion of clindamycin is used to maintain serum clindamycin concentrations above 4-6 mcg/mL in adults, an initial dose is given by rapid IV infusion prior to continuous IV infusion. (See Table 1.)
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for CLINDAMYCIN PHOSPHATE-D5W (clindamycin phosphate/dextrose 5 % in water):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Live Typhoid Vaccine/Antimicrobials SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1) CLINICAL EFFECTS: Vaccination may be ineffective. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3) DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3) |
VIVOTIF |
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Fecal Microbiota Spores/Antibiotics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1) CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1) DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores. |
VOWST |
There are 2 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Neuromuscular Blocking Agents/Lincosamides SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Lincosamides appear to augment the neuromuscular blocking effects of nondepolarizing muscle relaxants. CLINICAL EFFECTS: The effects of nondepolarizing neuromuscular relaxants may be prolonged leading to profound sedation, respiratory depression, coma, and/or death. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Monitor respiratory function of the patient and provide the necessary support. In patients who have received nondepolarizing muscle relaxants, avoid use of lincosamides in the recovery room. If concurrent use is necessary, monitor patients for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness. DISCUSSION: Lincomycin has been reported to augment the neuromuscular blocking effect of pancuronium in seven anesthetized patients. The effect was readily antagonized by neostigmine administration. In a case report, clindamycin produced prolonged neuromuscular blockade in a patient who had received pancuronium. Neostigmine was ineffective in antagonizing the blockade. |
ANECTINE, ATRACURIUM BESYLATE, BOTOX, BOTOX COSMETIC, CISATRACURIUM BESYLATE, DAXXIFY, DYSPORT, JEUVEAU, MYOBLOC, NIMBEX, QUELICIN, ROCURONIUM BROMIDE, SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE-NACL, VECURONIUM BROMIDE, VECURONIUM BROMIDE-WATER, XEOMIN |
| Clindamycin/Strong CYP3A4 Inducers SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Strong CYP3A4 inducers may induce the metabolism of clindamycin. CLINICAL EFFECTS: Concurrent or recent use of a strong CYP3A4 inducer may result in decreased antimicrobial activity of clindamycin. PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks. PATIENT MANAGEMENT: Monitor the response to clindamycin. Adjust the dose of clindamycin or consider administration of a non-interacting antimicrobial if necessary. DISCUSSION: The effects of the interaction develop over approximately one to two weeks after starting the inducer and reverse over a period of several weeks after stopping the inducer. Serum clindamycin concentrations may increase when the inducer is stopped. In an observational study, 6 patients treated concomitantly with clindamycin and rifampin showed significantly lower clindamycin trough concentrations. None of the patients reached the target clindamycin minimum concentration (Cmin) (1.7 mg/L).(2) A retrospective review of patients on concomitant clindamycin and rifampin showed a 82-93% decrease in the clindamycin median peak and trough concentrations.(3) Several other studies showed significant decreases in median peak and trough concentrations of clindamycin with concomitant rifampin.(4,6,7) In a study in patients on oral or intravenous clindamycin (600 mg three times daily), patients on concomitant rifampin showed a 43% increase in clindamycin clearance.(5) In another study, concomitant rifampin with intravenous or oral clindamycin led to a 2.7-fold and 7-fold increase in clindamycin clearance, respectively.(7) Strong CYP3A4 inducers linked to this monograph include: apalutamide, barbiturates, carbamazepine, encorafenib, enzalutamide, fosphenytoin, ivosidenib, lumacaftor, mitotane, phenobarbital, phenytoin, primidone, and St. John's Wort.(9) |
ASA-BUTALB-CAFFEINE-CODEINE, ASCOMP WITH CODEINE, BRAFTOVI, BUTALB-ACETAMINOPH-CAFF-CODEIN, BUTALBITAL, BUTALBITAL-ACETAMINOPHEN, BUTALBITAL-ACETAMINOPHEN-CAFFE, BUTALBITAL-ASPIRIN-CAFFEINE, CARBAMAZEPINE, CARBAMAZEPINE ER, CARBATROL, CEREBYX, DILANTIN, DILANTIN-125, DONNATAL, EPITOL, EQUETRO, ERLEADA, FIORICET, FIORICET WITH CODEINE, FOSPHENYTOIN SODIUM, LYSODREN, MITOTANE, MYSOLINE, ORKAMBI, PENTOBARBITAL SODIUM, PHENOBARBITAL, PHENOBARBITAL SODIUM, PHENOBARBITAL-BELLADONNA, PHENOBARBITAL-HYOSC-ATROP-SCOP, PHENOHYTRO, PHENYTEK, PHENYTOIN, PHENYTOIN SODIUM, PHENYTOIN SODIUM EXTENDED, PRIMIDONE, SEZABY, TEGRETOL, TEGRETOL XR, TENCON, TIBSOVO, XTANDI |
The following contraindication information is available for CLINDAMYCIN PHOSPHATE-D5W (clindamycin phosphate/dextrose 5 % in water):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 6 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Bloody stools |
| Clostridioides difficile infection |
| Crohn's disease |
| Diarrhea |
| Myasthenia gravis |
| Ulcerative colitis |
There are 3 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Atopic dermatitis |
| Disease of liver |
| Kidney disease with reduction in glomerular filtration rate (GFr) |
The following adverse reaction information is available for CLINDAMYCIN PHOSPHATE-D5W (clindamycin phosphate/dextrose 5 % in water):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 26 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Clostridioides difficile infection |
Abnormal hepatic function tests Allergic dermatitis Pruritus of skin Skin rash Urticaria |
| Rare/Very Rare |
|---|
|
Acute generalized exanthematous pustulosis Acute renal failure Agranulocytosis Anaphylaxis Angioedema Bullous dermatitis Cholestasis DRESS syndrome Drug-induced hepatitis Eosinophilia Erythema multiforme Esophageal ulcer Exfoliative dermatitis Hypersensitivity drug reaction Jaundice Kidney disease with reduction in glomerular filtration rate (GFr) Neutropenic disorder Stevens-johnson syndrome Thrombocytopenic disorder Toxic epidermal necrolysis |
There are 15 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Acute abdominal pain Diarrhea Nausea Vomiting |
Erythema Esophagitis Genital organ pruritus Oral candidiasis Vaginitis Vulvovaginal candidiasis |
| Rare/Very Rare |
|---|
|
Arthritis Azotemia Dysgeusia Maculopapular rash Thrombophlebitis |
The following precautions are available for CLINDAMYCIN PHOSPHATE-D5W (clindamycin phosphate/dextrose 5 % in water):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Reproduction studies in rats and mice using oral or parenteral dosages of clindamycin up to 600 mg/kg daily (3.2 and 1.6 times, respectively, the maximum recommended human oral dosage or 2.1 and 1.1 times, respectively, the maximum recommended human parenteral dosage on a mg/m2 basis) have not revealed evidence of teratogenicity. In clinical trials that included pregnant women, systemic clindamycin administered during the second and third trimesters was not associated with an increased frequency of congenital abnormalities. There are no adequate and well-controlled studies to date using clindamycin in pregnant women during the first trimester of pregnancy.
Because animal reproduction studies are not always predictive of human response, clindamycin should be used during pregnancy only when clearly needed. Clindamycin phosphate injection contains benzyl alcohol as a preservative; benzyl alcohol can cross the placenta. (See Cautions: Pediatric Precautions.)
Because animal reproduction studies are not always predictive of human response, clindamycin should be used during pregnancy only when clearly needed. Clindamycin phosphate injection contains benzyl alcohol as a preservative; benzyl alcohol can cross the placenta. (See Cautions: Pediatric Precautions.)
Clindamycin is distributed into milk (see Pharmacokinetics: Distribution), and has the potential to cause adverse effects on the GI flora of breast-fed infants. The manufacturer states that use of oral or IV clindamycin in the mother is not a reason to discontinue breast-feeding; however, it may be preferable to use an alternate anti-infective. If clindamycin is used in a breast-feeding mother, the infant should be monitored for possible adverse effects on GI flora, including diarrhea and candidiasis (thrush, diaper rash) or, rarely, blood in the stool indicating possible antibiotic-associated colitis. The benefits of breast-feeding and the importance of clindamycin to the woman should be considered along with potential adverse effects on the breast-fed child from the drug or from the underlying maternal condition.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for CLINDAMYCIN PHOSPHATE-D5W (clindamycin phosphate/dextrose 5 % in water):
WARNING: This medication may rarely cause a severe intestinal condition due to a bacteria called C. difficile. This condition may occur weeks to months after treatment has stopped.
Tell your doctor right away if you develop: diarrhea that doesn't stop, abdominal or stomach pain/cramping, blood/mucus in your stool. If you have these symptoms, do not use anti-diarrhea or opioid products because they may make symptoms worse.
WARNING: This medication may rarely cause a severe intestinal condition due to a bacteria called C. difficile. This condition may occur weeks to months after treatment has stopped.
Tell your doctor right away if you develop: diarrhea that doesn't stop, abdominal or stomach pain/cramping, blood/mucus in your stool. If you have these symptoms, do not use anti-diarrhea or opioid products because they may make symptoms worse.
The following icd codes are available for CLINDAMYCIN PHOSPHATE-D5W (clindamycin phosphate/dextrose 5 % in water)'s list of indications:
| Anaerobic endometritis | |
| B96.6 | Bacteroides fragilis [b. fragilis] as the cause of diseases classified elsewhere |
| B96.7 | Clostridium perfringens [c. perfringens] as the cause of diseases classified elsewhere |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| N71.0 | Acute inflammatory disease of uterus |
| N71.1 | Chronic inflammatory disease of uterus |
| N71.9 | Inflammatory disease of uterus, unspecified |
| O86.12 | Endometritis following delivery |
| Anaerobic joint infection | |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| M00.8 | Arthritis and polyarthritis due to other bacteria |
| M00.80 | Arthritis due to other bacteria, unspecified joint |
| M00.81 | Arthritis due to other bacteria, shoulder |
| M00.811 | Arthritis due to other bacteria, right shoulder |
| M00.812 | Arthritis due to other bacteria, left shoulder |
| M00.819 | Arthritis due to other bacteria, unspecified shoulder |
| M00.82 | Arthritis due to other bacteria, elbow |
| M00.821 | Arthritis due to other bacteria, right elbow |
| M00.822 | Arthritis due to other bacteria, left elbow |
| M00.829 | Arthritis due to other bacteria, unspecified elbow |
| M00.83 | Arthritis due to other bacteria, wrist |
| M00.831 | Arthritis due to other bacteria, right wrist |
| M00.832 | Arthritis due to other bacteria, left wrist |
| M00.839 | Arthritis due to other bacteria, unspecified wrist |
| M00.84 | Arthritis due to other bacteria, hand |
| M00.841 | Arthritis due to other bacteria, right hand |
| M00.842 | Arthritis due to other bacteria, left hand |
| M00.849 | Arthritis due to other bacteria, unspecified hand |
| M00.85 | Arthritis due to other bacteria, hip |
| M00.851 | Arthritis due to other bacteria, right hip |
| M00.852 | Arthritis due to other bacteria, left hip |
| M00.859 | Arthritis due to other bacteria, unspecified hip |
| M00.86 | Arthritis due to other bacteria, knee |
| M00.861 | Arthritis due to other bacteria, right knee |
| M00.862 | Arthritis due to other bacteria, left knee |
| M00.869 | Arthritis due to other bacteria, unspecified knee |
| M00.87 | Arthritis due to other bacteria, ankle and foot |
| M00.871 | Arthritis due to other bacteria, right ankle and foot |
| M00.872 | Arthritis due to other bacteria, left ankle and foot |
| M00.879 | Arthritis due to other bacteria, unspecified ankle and foot |
| M00.88 | Arthritis due to other bacteria, vertebrae |
| M00.89 | Polyarthritis due to other bacteria |
| Anaerobic lung abscess | |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| J85.1 | Abscess of lung with pneumonia |
| J85.2 | Abscess of lung without pneumonia |
| Anaerobic pelvic cellulitis | |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| N73.0 | Acute parametritis and pelvic cellulitis |
| N73.1 | Chronic parametritis and pelvic cellulitis |
| N73.2 | Unspecified parametritis and pelvic cellulitis |
| Anaerobic peritonitis | |
| B96.6 | Bacteroides fragilis [b. fragilis] as the cause of diseases classified elsewhere |
| B96.7 | Clostridium perfringens [c. perfringens] as the cause of diseases classified elsewhere |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| K65.0 | Generalized (acute) peritonitis |
| K65.2 | Spontaneous bacterial peritonitis |
| T85.71 | Infection and inflammatory reaction due to peritoneal dialysis catheter |
| T85.71xA | Infection and inflammatory reaction due to peritoneal dialysis catheter, initial encounter |
| Anaerobic pneumonia | |
| J15.8 | Pneumonia due to other specified bacteria |
| Anaerobic tubo-ovarian abscess | |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| N70 | Salpingitis and oophoritis |
| N70.0 | Acute salpingitis and oophoritis |
| N70.01 | Acute salpingitis |
| N70.02 | Acute oophoritis |
| N70.03 | Acute salpingitis and oophoritis |
| N70.1 | Chronic salpingitis and oophoritis |
| N70.11 | Chronic salpingitis |
| N70.12 | Chronic oophoritis |
| N70.13 | Chronic salpingitis and oophoritis |
| N70.9 | Salpingitis and oophoritis, unspecified |
| N70.91 | Salpingitis, unspecified |
| N70.92 | Oophoritis, unspecified |
| N70.93 | Salpingitis and oophoritis, unspecified |
| Clostridium perfringens empyema | |
| B96.7 | Clostridium perfringens [c. perfringens] as the cause of diseases classified elsewhere |
| Gas gangrene caused by clostridium perfringens | |
| A48.0 | Gas gangrene |
| Intra-abdominal anaerobic abscess | |
| B96.6 | Bacteroides fragilis [b. fragilis] as the cause of diseases classified elsewhere |
| B96.7 | Clostridium perfringens [c. perfringens] as the cause of diseases classified elsewhere |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| D73.3 | Abscess of spleen |
| K35.21 | Acute appendicitis with generalized peritonitis, with abscess |
| K35.210 | Acute appendicitis with generalized peritonitis, without perforation, with abscess |
| K35.211 | Acute appendicitis with generalized peritonitis, with perforation and abscess |
| K35.219 | Acute appendicitis with generalized peritonitis, with abscess, unspecified as to perforation |
| K35.33 | Acute appendicitis with perforation, localized peritonitis, and gangrene, with abscess |
| K50.014 | Crohn's disease of small intestine with abscess |
| K50.114 | Crohn's disease of large intestine with abscess |
| K50.814 | Crohn's disease of both small and large intestine with abscess |
| K50.914 | Crohn's disease, unspecified, with abscess |
| K51.014 | Ulcerative (chronic) pancolitis with abscess |
| K51.214 | Ulcerative (chronic) proctitis with abscess |
| K51.314 | Ulcerative (chronic) rectosigmoiditis with abscess |
| K51.414 | Inflammatory polyps of colon with abscess |
| K51.514 | Left sided colitis with abscess |
| K51.814 | Other ulcerative colitis with abscess |
| K51.914 | Ulcerative colitis, unspecified with abscess |
| K57.0 | Diverticulitis of small intestine with perforation and abscess |
| K57.00 | Diverticulitis of small intestine with perforation and abscess without bleeding |
| K57.01 | Diverticulitis of small intestine with perforation and abscess with bleeding |
| K57.2 | Diverticulitis of large intestine with perforation and abscess |
| K57.20 | Diverticulitis of large intestine with perforation and abscess without bleeding |
| K57.21 | Diverticulitis of large intestine with perforation and abscess with bleeding |
| K57.4 | Diverticulitis of both small and large intestine with perforation and abscess |
| K57.40 | Diverticulitis of both small and large intestine with perforation and abscess without bleeding |
| K57.41 | Diverticulitis of both small and large intestine with perforation and abscess with bleeding |
| K57.8 | Diverticulitis of intestine, part unspecified, with perforation and abscess |
| K57.80 | Diverticulitis of intestine, part unspecified, with perforation and abscess without bleeding |
| K57.81 | Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding |
| K63.0 | Abscess of intestine |
| K65.1 | Peritoneal abscess |
| K68.1 | Retroperitoneal abscess |
| K68.11 | Postprocedural retroperitoneal abscess |
| K68.12 | Psoas muscle abscess |
| K68.19 | Other retroperitoneal abscess |
| K75.0 | Abscess of liver |
| N15.1 | Renal and perinephric abscess |
| N34.0 | Urethral abscess |
| N41.2 | Abscess of prostate |
| Pneumococcal pneumonia | |
| J13 | Pneumonia due to streptococcus pneumoniae |
| Postsurgical vaginal cuff anaerobic infections | |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| N76.0 | Acute vaginitis |
| T81.43 | Infection following a procedure, organ and space surgical site |
| T81.43xA | Infection following a procedure, organ and space surgical site, initial encounter |
| Sepsis caused by anaerobic bacteria | |
| A41.4 | Sepsis due to anaerobes |
| P36.5 | Sepsis of newborn due to anaerobes |
| Skin and skin structure anaerobic infection | |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| Skin and skin structure strep. pyogenes infection | |
| B95.0 | Streptococcus, group a, as the cause of diseases classified elsewhere |
| B95.4 | Other streptococcus as the cause of diseases classified elsewhere |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| Staphylococcal pneumonia | |
| J15.2 | Pneumonia due to staphylococcus |
| J15.20 | Pneumonia due to staphylococcus, unspecified |
| J15.21 | Pneumonia due to staphylococcus aureus |
| J15.211 | Pneumonia due to methicillin susceptible staphylococcus aureus |
| J15.212 | Pneumonia due to methicillin resistant staphylococcus aureus |
| J15.29 | Pneumonia due to other staphylococcus |
| Staphylococcal septicemia | |
| A41.0 | Sepsis due to staphylococcus aureus |
| A41.01 | Sepsis due to methicillin susceptible staphylococcus aureus |
| A41.02 | Sepsis due to methicillin resistant staphylococcus aureus |
| A41.1 | Sepsis due to other specified staphylococcus |
| A41.2 | Sepsis due to unspecified staphylococcus |
| P36.2 | Sepsis of newborn due to staphylococcus aureus |
| P36.3 | Sepsis of newborn due to other and unspecified staphylococci |
| P36.30 | Sepsis of newborn due to unspecified staphylococci |
| P36.39 | Sepsis of newborn due to other staphylococci |
| Staphylococcus aureus osteomyelitis | |
| B95.6 | Staphylococcus aureus as the cause of diseases classified elsewhere |
| B95.61 | Methicillin susceptible staphylococcus aureus infection as the cause of diseases classified elsewhere |
| B95.62 | Methicillin resistant staphylococcus aureus infection as the cause of diseases classified elsewhere |
| H05.02 | Osteomyelitis of orbit |
| H05.021 | Osteomyelitis of right orbit |
| H05.022 | Osteomyelitis of left orbit |
| H05.023 | Osteomyelitis of bilateral orbits |
| H05.029 | Osteomyelitis of unspecified orbit |
| M46.2 | Osteomyelitis of vertebra |
| M46.20 | Osteomyelitis of vertebra, site unspecified |
| M46.21 | Osteomyelitis of vertebra, occipito-atlanto-axial region |
| M46.22 | Osteomyelitis of vertebra, cervical region |
| M46.23 | Osteomyelitis of vertebra, cervicothoracic region |
| M46.24 | Osteomyelitis of vertebra, thoracic region |
| M46.25 | Osteomyelitis of vertebra, thoracolumbar region |
| M46.26 | Osteomyelitis of vertebra, lumbar region |
| M46.27 | Osteomyelitis of vertebra, lumbosacral region |
| M46.28 | Osteomyelitis of vertebra, sacral and sacrococcygeal region |
| M86 | Osteomyelitis |
| M86.0 | Acute hematogenous osteomyelitis |
| M86.00 | Acute hematogenous osteomyelitis, unspecified site |
| M86.01 | Acute hematogenous osteomyelitis, shoulder |
| M86.011 | Acute hematogenous osteomyelitis, right shoulder |
| M86.012 | Acute hematogenous osteomyelitis, left shoulder |
| M86.019 | Acute hematogenous osteomyelitis, unspecified shoulder |
| M86.02 | Acute hematogenous osteomyelitis, humerus |
| M86.021 | Acute hematogenous osteomyelitis, right humerus |
| M86.022 | Acute hematogenous osteomyelitis, left humerus |
| M86.029 | Acute hematogenous osteomyelitis, unspecified humerus |
| M86.03 | Acute hematogenous osteomyelitis, radius and ulna |
| M86.031 | Acute hematogenous osteomyelitis, right radius and ulna |
| M86.032 | Acute hematogenous osteomyelitis, left radius and ulna |
| M86.039 | Acute hematogenous osteomyelitis, unspecified radius and ulna |
| M86.04 | Acute hematogenous osteomyelitis, hand |
| M86.041 | Acute hematogenous osteomyelitis, right hand |
| M86.042 | Acute hematogenous osteomyelitis, left hand |
| M86.049 | Acute hematogenous osteomyelitis, unspecified hand |
| M86.05 | Acute hematogenous osteomyelitis, femur |
| M86.051 | Acute hematogenous osteomyelitis, right femur |
| M86.052 | Acute hematogenous osteomyelitis, left femur |
| M86.059 | Acute hematogenous osteomyelitis, unspecified femur |
| M86.06 | Acute hematogenous osteomyelitis, tibia and fibula |
| M86.061 | Acute hematogenous osteomyelitis, right tibia and fibula |
| M86.062 | Acute hematogenous osteomyelitis, left tibia and fibula |
| M86.069 | Acute hematogenous osteomyelitis, unspecified tibia and fibula |
| M86.07 | Acute hematogenous osteomyelitis, ankle and foot |
| M86.071 | Acute hematogenous osteomyelitis, right ankle and foot |
| M86.072 | Acute hematogenous osteomyelitis, left ankle and foot |
| M86.079 | Acute hematogenous osteomyelitis, unspecified ankle and foot |
| M86.08 | Acute hematogenous osteomyelitis, other sites |
| M86.09 | Acute hematogenous osteomyelitis, multiple sites |
| M86.1 | Other acute osteomyelitis |
| M86.10 | Other acute osteomyelitis, unspecified site |
| M86.11 | Other acute osteomyelitis, shoulder |
| M86.111 | Other acute osteomyelitis, right shoulder |
| M86.112 | Other acute osteomyelitis, left shoulder |
| M86.119 | Other acute osteomyelitis, unspecified shoulder |
| M86.12 | Other acute osteomyelitis, humerus |
| M86.121 | Other acute osteomyelitis, right humerus |
| M86.122 | Other acute osteomyelitis, left humerus |
| M86.129 | Other acute osteomyelitis, unspecified humerus |
| M86.13 | Other acute osteomyelitis, radius and ulna |
| M86.131 | Other acute osteomyelitis, right radius and ulna |
| M86.132 | Other acute osteomyelitis, left radius and ulna |
| M86.139 | Other acute osteomyelitis, unspecified radius and ulna |
| M86.14 | Other acute osteomyelitis, hand |
| M86.141 | Other acute osteomyelitis, right hand |
| M86.142 | Other acute osteomyelitis, left hand |
| M86.149 | Other acute osteomyelitis, unspecified hand |
| M86.15 | Other acute osteomyelitis, femur |
| M86.151 | Other acute osteomyelitis, right femur |
| M86.152 | Other acute osteomyelitis, left femur |
| M86.159 | Other acute osteomyelitis, unspecified femur |
| M86.16 | Other acute osteomyelitis, tibia and fibula |
| M86.161 | Other acute osteomyelitis, right tibia and fibula |
| M86.162 | Other acute osteomyelitis, left tibia and fibula |
| M86.169 | Other acute osteomyelitis, unspecified tibia and fibula |
| M86.17 | Other acute osteomyelitis, ankle and foot |
| M86.171 | Other acute osteomyelitis, right ankle and foot |
| M86.172 | Other acute osteomyelitis, left ankle and foot |
| M86.179 | Other acute osteomyelitis, unspecified ankle and foot |
| M86.18 | Other acute osteomyelitis, other site |
| M86.19 | Other acute osteomyelitis, multiple sites |
| M86.2 | Subacute osteomyelitis |
| M86.20 | Subacute osteomyelitis, unspecified site |
| M86.21 | Subacute osteomyelitis, shoulder |
| M86.211 | Subacute osteomyelitis, right shoulder |
| M86.212 | Subacute osteomyelitis, left shoulder |
| M86.219 | Subacute osteomyelitis, unspecified shoulder |
| M86.22 | Subacute osteomyelitis, humerus |
| M86.221 | Subacute osteomyelitis, right humerus |
| M86.222 | Subacute osteomyelitis, left humerus |
| M86.229 | Subacute osteomyelitis, unspecified humerus |
| M86.23 | Subacute osteomyelitis, radius and ulna |
| M86.231 | Subacute osteomyelitis, right radius and ulna |
| M86.232 | Subacute osteomyelitis, left radius and ulna |
| M86.239 | Subacute osteomyelitis, unspecified radius and ulna |
| M86.24 | Subacute osteomyelitis, hand |
| M86.241 | Subacute osteomyelitis, right hand |
| M86.242 | Subacute osteomyelitis, left hand |
| M86.249 | Subacute osteomyelitis, unspecified hand |
| M86.25 | Subacute osteomyelitis, femur |
| M86.251 | Subacute osteomyelitis, right femur |
| M86.252 | Subacute osteomyelitis, left femur |
| M86.259 | Subacute osteomyelitis, unspecified femur |
| M86.26 | Subacute osteomyelitis, tibia and fibula |
| M86.261 | Subacute osteomyelitis, right tibia and fibula |
| M86.262 | Subacute osteomyelitis, left tibia and fibula |
| M86.269 | Subacute osteomyelitis, unspecified tibia and fibula |
| M86.27 | Subacute osteomyelitis, ankle and foot |
| M86.271 | Subacute osteomyelitis, right ankle and foot |
| M86.272 | Subacute osteomyelitis, left ankle and foot |
| M86.279 | Subacute osteomyelitis, unspecified ankle and foot |
| M86.28 | Subacute osteomyelitis, other site |
| M86.29 | Subacute osteomyelitis, multiple sites |
| M86.3 | Chronic multifocal osteomyelitis |
| M86.30 | Chronic multifocal osteomyelitis, unspecified site |
| M86.31 | Chronic multifocal osteomyelitis, shoulder |
| M86.311 | Chronic multifocal osteomyelitis, right shoulder |
| M86.312 | Chronic multifocal osteomyelitis, left shoulder |
| M86.319 | Chronic multifocal osteomyelitis, unspecified shoulder |
| M86.32 | Chronic multifocal osteomyelitis, humerus |
| M86.321 | Chronic multifocal osteomyelitis, right humerus |
| M86.322 | Chronic multifocal osteomyelitis, left humerus |
| M86.329 | Chronic multifocal osteomyelitis, unspecified humerus |
| M86.33 | Chronic multifocal osteomyelitis, radius and ulna |
| M86.331 | Chronic multifocal osteomyelitis, right radius and ulna |
| M86.332 | Chronic multifocal osteomyelitis, left radius and ulna |
| M86.339 | Chronic multifocal osteomyelitis, unspecified radius and ulna |
| M86.34 | Chronic multifocal osteomyelitis, hand |
| M86.341 | Chronic multifocal osteomyelitis, right hand |
| M86.342 | Chronic multifocal osteomyelitis, left hand |
| M86.349 | Chronic multifocal osteomyelitis, unspecified hand |
| M86.35 | Chronic multifocal osteomyelitis, femur |
| M86.351 | Chronic multifocal osteomyelitis, right femur |
| M86.352 | Chronic multifocal osteomyelitis, left femur |
| M86.359 | Chronic multifocal osteomyelitis, unspecified femur |
| M86.36 | Chronic multifocal osteomyelitis, tibia and fibula |
| M86.361 | Chronic multifocal osteomyelitis, right tibia and fibula |
| M86.362 | Chronic multifocal osteomyelitis, left tibia and fibula |
| M86.369 | Chronic multifocal osteomyelitis, unspecified tibia and fibula |
| M86.37 | Chronic multifocal osteomyelitis, ankle and foot |
| M86.371 | Chronic multifocal osteomyelitis, right ankle and foot |
| M86.372 | Chronic multifocal osteomyelitis, left ankle and foot |
| M86.379 | Chronic multifocal osteomyelitis, unspecified ankle and foot |
| M86.38 | Chronic multifocal osteomyelitis, other site |
| M86.39 | Chronic multifocal osteomyelitis, multiple sites |
| M86.4 | Chronic osteomyelitis with draining sinus |
| M86.40 | Chronic osteomyelitis with draining sinus, unspecified site |
| M86.41 | Chronic osteomyelitis with draining sinus, shoulder |
| M86.411 | Chronic osteomyelitis with draining sinus, right shoulder |
| M86.412 | Chronic osteomyelitis with draining sinus, left shoulder |
| M86.419 | Chronic osteomyelitis with draining sinus, unspecified shoulder |
| M86.42 | Chronic osteomyelitis with draining sinus, humerus |
| M86.421 | Chronic osteomyelitis with draining sinus, right humerus |
| M86.422 | Chronic osteomyelitis with draining sinus, left humerus |
| M86.429 | Chronic osteomyelitis with draining sinus, unspecified humerus |
| M86.43 | Chronic osteomyelitis with draining sinus, radius and ulna |
| M86.431 | Chronic osteomyelitis with draining sinus, right radius and ulna |
| M86.432 | Chronic osteomyelitis with draining sinus, left radius and ulna |
| M86.439 | Chronic osteomyelitis with draining sinus, unspecified radius and ulna |
| M86.44 | Chronic osteomyelitis with draining sinus, hand |
| M86.441 | Chronic osteomyelitis with draining sinus, right hand |
| M86.442 | Chronic osteomyelitis with draining sinus, left hand |
| M86.449 | Chronic osteomyelitis with draining sinus, unspecified hand |
| M86.45 | Chronic osteomyelitis with draining sinus, femur |
| M86.451 | Chronic osteomyelitis with draining sinus, right femur |
| M86.452 | Chronic osteomyelitis with draining sinus, left femur |
| M86.459 | Chronic osteomyelitis with draining sinus, unspecified femur |
| M86.46 | Chronic osteomyelitis with draining sinus, tibia and fibula |
| M86.461 | Chronic osteomyelitis with draining sinus, right tibia and fibula |
| M86.462 | Chronic osteomyelitis with draining sinus, left tibia and fibula |
| M86.469 | Chronic osteomyelitis with draining sinus, unspecified tibia and fibula |
| M86.47 | Chronic osteomyelitis with draining sinus, ankle and foot |
| M86.471 | Chronic osteomyelitis with draining sinus, right ankle and foot |
| M86.472 | Chronic osteomyelitis with draining sinus, left ankle and foot |
| M86.479 | Chronic osteomyelitis with draining sinus, unspecified ankle and foot |
| M86.48 | Chronic osteomyelitis with draining sinus, other site |
| M86.49 | Chronic osteomyelitis with draining sinus, multiple sites |
| M86.5 | Other chronic hematogenous osteomyelitis |
| M86.50 | Other chronic hematogenous osteomyelitis, unspecified site |
| M86.51 | Other chronic hematogenous osteomyelitis, shoulder |
| M86.511 | Other chronic hematogenous osteomyelitis, right shoulder |
| M86.512 | Other chronic hematogenous osteomyelitis, left shoulder |
| M86.519 | Other chronic hematogenous osteomyelitis, unspecified shoulder |
| M86.52 | Other chronic hematogenous osteomyelitis, humerus |
| M86.521 | Other chronic hematogenous osteomyelitis, right humerus |
| M86.522 | Other chronic hematogenous osteomyelitis, left humerus |
| M86.529 | Other chronic hematogenous osteomyelitis, unspecified humerus |
| M86.53 | Other chronic hematogenous osteomyelitis, radius and ulna |
| M86.531 | Other chronic hematogenous osteomyelitis, right radius and ulna |
| M86.532 | Other chronic hematogenous osteomyelitis, left radius and ulna |
| M86.539 | Other chronic hematogenous osteomyelitis, unspecified radius and ulna |
| M86.54 | Other chronic hematogenous osteomyelitis, hand |
| M86.541 | Other chronic hematogenous osteomyelitis, right hand |
| M86.542 | Other chronic hematogenous osteomyelitis, left hand |
| M86.549 | Other chronic hematogenous osteomyelitis, unspecified hand |
| M86.55 | Other chronic hematogenous osteomyelitis, femur |
| M86.551 | Other chronic hematogenous osteomyelitis, right femur |
| M86.552 | Other chronic hematogenous osteomyelitis, left femur |
| M86.559 | Other chronic hematogenous osteomyelitis, unspecified femur |
| M86.56 | Other chronic hematogenous osteomyelitis, tibia and fibula |
| M86.561 | Other chronic hematogenous osteomyelitis, right tibia and fibula |
| M86.562 | Other chronic hematogenous osteomyelitis, left tibia and fibula |
| M86.569 | Other chronic hematogenous osteomyelitis, unspecified tibia and fibula |
| M86.57 | Other chronic hematogenous osteomyelitis, ankle and foot |
| M86.571 | Other chronic hematogenous osteomyelitis, right ankle and foot |
| M86.572 | Other chronic hematogenous osteomyelitis, left ankle and foot |
| M86.579 | Other chronic hematogenous osteomyelitis, unspecified ankle and foot |
| M86.58 | Other chronic hematogenous osteomyelitis, other site |
| M86.59 | Other chronic hematogenous osteomyelitis, multiple sites |
| M86.6 | Other chronic osteomyelitis |
| M86.60 | Other chronic osteomyelitis, unspecified site |
| M86.61 | Other chronic osteomyelitis, shoulder |
| M86.611 | Other chronic osteomyelitis, right shoulder |
| M86.612 | Other chronic osteomyelitis, left shoulder |
| M86.619 | Other chronic osteomyelitis, unspecified shoulder |
| M86.62 | Other chronic osteomyelitis, humerus |
| M86.621 | Other chronic osteomyelitis, right humerus |
| M86.622 | Other chronic osteomyelitis, left humerus |
| M86.629 | Other chronic osteomyelitis, unspecified humerus |
| M86.63 | Other chronic osteomyelitis, radius and ulna |
| M86.631 | Other chronic osteomyelitis, right radius and ulna |
| M86.632 | Other chronic osteomyelitis, left radius and ulna |
| M86.639 | Other chronic osteomyelitis, unspecified radius and ulna |
| M86.64 | Other chronic osteomyelitis, hand |
| M86.641 | Other chronic osteomyelitis, right hand |
| M86.642 | Other chronic osteomyelitis, left hand |
| M86.649 | Other chronic osteomyelitis, unspecified hand |
| M86.65 | Other chronic osteomyelitis, thigh |
| M86.651 | Other chronic osteomyelitis, right thigh |
| M86.652 | Other chronic osteomyelitis, left thigh |
| M86.659 | Other chronic osteomyelitis, unspecified thigh |
| M86.66 | Other chronic osteomyelitis, tibia and fibula |
| M86.661 | Other chronic osteomyelitis, right tibia and fibula |
| M86.662 | Other chronic osteomyelitis, left tibia and fibula |
| M86.669 | Other chronic osteomyelitis, unspecified tibia and fibula |
| M86.67 | Other chronic osteomyelitis, ankle and foot |
| M86.671 | Other chronic osteomyelitis, right ankle and foot |
| M86.672 | Other chronic osteomyelitis, left ankle and foot |
| M86.679 | Other chronic osteomyelitis, unspecified ankle and foot |
| M86.68 | Other chronic osteomyelitis, other site |
| M86.69 | Other chronic osteomyelitis, multiple sites |
| M86.8 | Other osteomyelitis |
| M86.8x | Other osteomyelitis |
| M86.8x0 | Other osteomyelitis, multiple sites |
| M86.8x1 | Other osteomyelitis, shoulder |
| M86.8x2 | Other osteomyelitis, upper arm |
| M86.8x3 | Other osteomyelitis, forearm |
| M86.8x4 | Other osteomyelitis, hand |
| M86.8x5 | Other osteomyelitis, thigh |
| M86.8x6 | Other osteomyelitis, lower leg |
| M86.8x7 | Other osteomyelitis, ankle and foot |
| M86.8x8 | Other osteomyelitis, other site |
| M86.8x9 | Other osteomyelitis, unspecified sites |
| M86.9 | Osteomyelitis, unspecified |
| Staphylococcus aureus skin and skin structure infection | |
| B95.6 | Staphylococcus aureus as the cause of diseases classified elsewhere |
| H60.1 | Cellulitis of external ear |
| H60.10 | Cellulitis of external ear, unspecified ear |
| H60.11 | Cellulitis of right external ear |
| H60.12 | Cellulitis of left external ear |
| H60.13 | Cellulitis of external ear, bilateral |
| J34.0 | Abscess, furuncle and carbuncle of nose |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L02.0 | Cutaneous abscess, furuncle and carbuncle of face |
| L02.02 | Furuncle of face |
| L02.03 | Carbuncle of face |
| L02.1 | Cutaneous abscess, furuncle and carbuncle of neck |
| L02.12 | Furuncle of neck |
| L02.13 | Carbuncle of neck |
| L02.2 | Cutaneous abscess, furuncle and carbuncle of trunk |
| L02.22 | Furuncle of trunk |
| L02.221 | Furuncle of abdominal wall |
| L02.222 | Furuncle of back [any part, except buttock] |
| L02.223 | Furuncle of chest wall |
| L02.224 | Furuncle of groin |
| L02.225 | Furuncle of perineum |
| L02.226 | Furuncle of umbilicus |
| L02.229 | Furuncle of trunk, unspecified |
| L02.23 | Carbuncle of trunk |
| L02.231 | Carbuncle of abdominal wall |
| L02.232 | Carbuncle of back [any part, except buttock] |
| L02.233 | Carbuncle of chest wall |
| L02.234 | Carbuncle of groin |
| L02.235 | Carbuncle of perineum |
| L02.236 | Carbuncle of umbilicus |
| L02.239 | Carbuncle of trunk, unspecified |
| L02.3 | Cutaneous abscess, furuncle and carbuncle of buttock |
| L02.32 | Furuncle of buttock |
| L02.33 | Carbuncle of buttock |
| L02.4 | Cutaneous abscess, furuncle and carbuncle of limb |
| L02.42 | Furuncle of limb |
| L02.421 | Furuncle of right axilla |
| L02.422 | Furuncle of left axilla |
| L02.423 | Furuncle of right upper limb |
| L02.424 | Furuncle of left upper limb |
| L02.425 | Furuncle of right lower limb |
| L02.426 | Furuncle of left lower limb |
| L02.429 | Furuncle of limb, unspecified |
| L02.43 | Carbuncle of limb |
| L02.431 | Carbuncle of right axilla |
| L02.432 | Carbuncle of left axilla |
| L02.433 | Carbuncle of right upper limb |
| L02.434 | Carbuncle of left upper limb |
| L02.435 | Carbuncle of right lower limb |
| L02.436 | Carbuncle of left lower limb |
| L02.439 | Carbuncle of limb, unspecified |
| L02.5 | Cutaneous abscess, furuncle and carbuncle of hand |
| L02.52 | Furuncle hand |
| L02.521 | Furuncle right hand |
| L02.522 | Furuncle left hand |
| L02.529 | Furuncle unspecified hand |
| L02.53 | Carbuncle of hand |
| L02.531 | Carbuncle of right hand |
| L02.532 | Carbuncle of left hand |
| L02.539 | Carbuncle of unspecified hand |
| L02.6 | Cutaneous abscess, furuncle and carbuncle of foot |
| L02.62 | Furuncle of foot |
| L02.621 | Furuncle of right foot |
| L02.622 | Furuncle of left foot |
| L02.629 | Furuncle of unspecified foot |
| L02.63 | Carbuncle of foot |
| L02.631 | Carbuncle of right foot |
| L02.632 | Carbuncle of left foot |
| L02.639 | Carbuncle of unspecified foot |
| L02.8 | Cutaneous abscess, furuncle and carbuncle of other sites |
| L02.82 | Furuncle of other sites |
| L02.821 | Furuncle of head [any part, except face] |
| L02.828 | Furuncle of other sites |
| L02.83 | Carbuncle of other sites |
| L02.831 | Carbuncle of head [any part, except face] |
| L02.838 | Carbuncle of other sites |
| L02.9 | Cutaneous abscess, furuncle and carbuncle, unspecified |
| L02.92 | Furuncle, unspecified |
| L02.93 | Carbuncle, unspecified |
| L03.01 | Cellulitis of finger |
| L03.011 | Cellulitis of right finger |
| L03.012 | Cellulitis of left finger |
| L03.019 | Cellulitis of unspecified finger |
| L03.03 | Cellulitis of toe |
| L03.031 | Cellulitis of right toe |
| L03.032 | Cellulitis of left toe |
| L03.039 | Cellulitis of unspecified toe |
| L03.1 | Cellulitis and acute lymphangitis of other parts of limb |
| L03.11 | Cellulitis of other parts of limb |
| L03.111 | Cellulitis of right axilla |
| L03.112 | Cellulitis of left axilla |
| L03.113 | Cellulitis of right upper limb |
| L03.114 | Cellulitis of left upper limb |
| L03.115 | Cellulitis of right lower limb |
| L03.116 | Cellulitis of left lower limb |
| L03.119 | Cellulitis of unspecified part of limb |
| L03.2 | Cellulitis and acute lymphangitis of face and neck |
| L03.21 | Cellulitis and acute lymphangitis of face |
| L03.211 | Cellulitis of face |
| L03.22 | Cellulitis and acute lymphangitis of neck |
| L03.221 | Cellulitis of neck |
| L03.3 | Cellulitis and acute lymphangitis of trunk |
| L03.31 | Cellulitis of trunk |
| L03.311 | Cellulitis of abdominal wall |
| L03.312 | Cellulitis of back [any part except buttock] |
| L03.313 | Cellulitis of chest wall |
| L03.314 | Cellulitis of groin |
| L03.315 | Cellulitis of perineum |
| L03.316 | Cellulitis of umbilicus |
| L03.317 | Cellulitis of buttock |
| L03.319 | Cellulitis of trunk, unspecified |
| L03.8 | Cellulitis and acute lymphangitis of other sites |
| L03.81 | Cellulitis of other sites |
| L03.811 | Cellulitis of head [any part, except face] |
| L03.818 | Cellulitis of other sites |
| L03.9 | Cellulitis and acute lymphangitis, unspecified |
| L03.90 | Cellulitis, unspecified |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| N48.22 | Cellulitis of corpus cavernosum and penis |
| Streptococcal pneumonia | |
| J13 | Pneumonia due to streptococcus pneumoniae |
| J15.3 | Pneumonia due to streptococcus, group B |
| J15.4 | Pneumonia due to other streptococci |
| Streptococcal septicemia | |
| A40 | Streptococcal sepsis |
| A40.0 | Sepsis due to streptococcus, group A |
| A40.1 | Sepsis due to streptococcus, group B |
| A40.3 | Sepsis due to streptococcus pneumoniae |
| A40.8 | Other streptococcal sepsis |
| A40.9 | Streptococcal sepsis, unspecified |
| P36.0 | Sepsis of newborn due to streptococcus, group B |
| P36.1 | Sepsis of newborn due to other and unspecified streptococci |
| P36.10 | Sepsis of newborn due to unspecified streptococci |
| P36.19 | Sepsis of newborn due to other streptococci |
Formulary Reference Tool